An Open Label Study of the Effect of Rituxan, High Dose Methotrexate and High Dose Cytarabine on Response Rate in Patients With Primary Central Nervous System Lymphoma.

Trial Profile

An Open Label Study of the Effect of Rituxan, High Dose Methotrexate and High Dose Cytarabine on Response Rate in Patients With Primary Central Nervous System Lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2014

At a glance

  • Drugs Rituximab (Primary) ; Cytarabine; Methotrexate
  • Indications CNS cancer; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 15 Jul 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 12 Mar 2010 Actual patient number (5) added as reported by ClinicalTrials.gov.
    • 17 Jul 2009 Actual end date changed from Mar 2009 to May 2009 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top